HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, W. Articles by Lee, R. J. Search for Related Content PubMed PubMed Citation Articles by Guo, W. Articles by Lee, R. J.

^99mTc-HYNIC-Folate: A Novel Receptor-Based Targeted Radiopharmaceutical for Tumor Imaging

Division of Pharmaceutics and Pharmaceutical Chemistry and Division of Pharmacy Practice and Administration, College of Pharmacy, Ohio State University, Columbus, Ohio

Correspondence: For correspondence or reprints contact: Robert J. Lee, PhD, Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, Ohio State University, 542 LM Parks Hall, 500 W. 12th Ave., Columbus, OH 43210.

ABSTRACT

The folate receptor is overexpressed in a wide variety of human tumors. Conjugates of folate have been shown to be selectively taken up by tumor cells via the folate receptor. In this study, a novel radiopharmaceutical, ^99mTc-6-hydrazinonicotinamido-hydrazido (HYNIC)-folate, was synthesized and evaluated for its efficacy as a targeted agent for the imaging of tumors that overexpress the folate receptor. Methods: HYNIC-folate was synthesized and radiolabeled with ^99mTc using tricine and trisodium triphenylphosphine-3,3',3''-trisulfonate as coligands. The receptor binding properties of ^99mTc-HYNIC-folate were studied in cultured tumor cells that overexpress the folate receptor. The tumor-localizing properties of ^99mTc-HYNIC-folate were then evaluated in C57BL/6 mice bearing subcutaneously implanted folate receptor-positive syngeneic tumors. Tissue distribution was determined at two different time points, and gamma camera images were collected on two animals. Results: The folate receptor mediated uptake of ^99mTc-HYNIC-folate by cultured tumor cells was approximately 300 times higher than the nonspecific binding determined in the presence of 1 mmoI/L free folic acid. Excellent tumor selectivity was also shown in the animal model; tumor-to blood ratios reached 55 ± 19 and 81 ± 6 at 4 and 24 h after injection, respectively. Tumor uptake of the radiotracer was blocked by the co-injection of 100 µg free folate. Tumors were clearly identifiable on the gamma camera images, with the kidneys and the bladder as the only normal organs showing high levels of the radiotracer. Conclusion: ^99mTc-HYNIC-folate is a promising, novel receptor-specific radiopharmaceutical with potential applications in the imaging of human tumors.

Key Words: ^99mTc • folate receptor • tumor imaging

This article has been cited by other articles:

				C. Muller, R. Schibli, E. P. Krenning, and M. de Jong Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer J. Nucl. Med., April 1, 2008; 49(4): 623 - 629. [Abstract] [Full Text] [PDF]

				C. Muller, F. Forrer, R. Schibli, E. P. Krenning, and M. de Jong SPECT Study of Folate Receptor-Positive Malignant and Normal Tissues in Mice Using a Novel 99mTc-Radiofolate J. Nucl. Med., February 1, 2008; 49(2): 310 - 317. [Abstract] [Full Text] [PDF]

				A. Bettio, M. Honer, C. Muller, M. Bruhlmeier, U. Muller, R. Schibli, V. Groehn, A. P. Schubiger, and S. M. Ametamey Synthesis and Preclinical Evaluation of a Folic Acid Derivative Labeled with 18F for PET Imaging of Folate Receptor-Positive Tumors J. Nucl. Med., July 1, 2006; 47(7): 1153 - 1160. [Abstract] [Full Text] [PDF]

				J. A. Reddy, L.-C. Xu, N. Parker, M. Vetzel, and C. P. Leamon Preclinical Evaluation of 99mTc-EC20 for Imaging Folate Receptor-Positive Tumors J. Nucl. Med., May 1, 2004; 45(5): 857 - 866. [Abstract] [Full Text] [PDF]

				B. A. Siegel, F. Dehdashti, D. G. Mutch, D. A. Podoloff, R. Wendt, G. P. Sutton, R. W. Burt, P. R. Ellis, C. J. Mathias, M. A. Green, et al. Evaluation of 111In-DTPA-Folate as a Receptor-Targeted Diagnostic Agent for Ovarian Cancer: Initial Clinical Results J. Nucl. Med., May 1, 2003; 44(5): 700 - 707. [Abstract] [Full Text] [PDF]